Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 9, 2026
- MBX Biosciences began enrollment in the pivotal Phase 3 oPTimize trial of once-weekly canvuparatide. Cash and investments were $481.6 million at September 30, 2026, expected to fund operations into 2029; third-quarter net loss was $62.4 million.
The audio replay and transcript follow the call.